Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sangamo Therapeutics (NQ: SGMO ) 2.470 +0.310 (+14.35%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sangamo Therapeutics < Previous 1 2 3 Next > Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast November 04, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 October 22, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results August 06, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases August 06, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast July 30, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate July 24, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA July 11, 2024 Via AB Newswire Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results May 09, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing May 09, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast May 02, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 22, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering March 22, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results March 13, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs March 13, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast March 12, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease February 12, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile February 05, 2024 From Sangamo Therapeutics, Inc. Via Business Wire 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results November 01, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast October 25, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) October 24, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit September 20, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results August 08, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast August 01, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing July 20, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids July 17, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease June 29, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease May 22, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer May 16, 2023 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) May 02, 2023 From Sangamo Therapeutics, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
